Actually, KIT D816V gain-of-function mutation is a well-characterized oncogenic event and identified in more than 80% of systemic mastocytosis, whereas the equivalent CSF-1R D802V mutation has not been found in human tumors [17]. This evidence concerns the gene KIT and systemic mastocytosis.